Skip to Main Content

Good morning, everyone, and how are you today? The sun is trying to peek through a muggy haze descending this morning on the Pharmalot campus, where our official mascot is lounging about and assorted birds and bugs can be heard in the distance. As for us, we are immersed in our usual routine of foraging for interesting items and brewing cups of stimulation. It is, after all, another busy day. No doubt, it is the same for you. So here are some tidbits to help you along. Hope today proves successful, and keep in touch. …

Bluebird Bio (BLUE) is winding down its European commercial operations because achieving appropriate value recognition in Europe is untenable for a small innovative company at this time, Pharmaphorum notes. The company previously pulled out of Germany over pricing disputes. At the same time, its stock dropped 25.9% after disclosing new safety issues with an experimental gene therapy under development to treat cerebral adrenoleukodystrophy, a rare genetic condition. A participant developed myelodysplastic syndrome, a type of cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment